Discover your next big idea at PACK EXPO Las Vegas this September
Experience a breakthrough in packaging & processing and transform your business with solutions from 2,300 suppliers spanning all industries.
REGISTER NOW & SAVE

Caffeine popularity problems

Lack of labeling information for levels could harm sensitive and at-risk consumers.

Rising popularity of high-caffeine drinks in U.S....could bring problems, according to a recent report in the Journal of Analytical Toxicology. Medical researchers argue that the high caffeine content in drinks should be disclosed on nutritional labels. The Food and Drug Administration currently requires manufacturers to note the presence of caffeine, but not the specific quantity. "That could deliver an unpleasant surprise to certain consumers who may not realize what they are drinking--particularly children, pregnant women and adults with hypertension, heart disease or excessive anxiety."

Source: Rochester Democrat and Chronicle

This item was from the June 22 issue of Global Packaging Minute, a monthly read of "hard-hitting and off-beat packaging news from around the world," edited by Packaging World associate publisher Jim Chrzan.

List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO
Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report